Peptide library
Your guide to this compound.
Very small human pigmentation and erectile-response studies are not long-term safety evidence. Pigmentation is not proof of ultraviolet protection; related afamelanotide approval does not authorize this molecule.
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Source 1 · pubmed.ncbi.nlm.nih.gov
Very small historical studies of healthy men and men with psychogenic erectile dysfunction; no broad consumer tanning population established.
Early studies observed pigmentation and erectile responses alongside adverse effects. They do not establish long-term safety, a consumer tanning schedule or protection from ultraviolet radiation.
Australia: TGA states that melanotan is not approved as a tanning agent and does not replace sunscreen protection. US: FDA lists Melanotan II among withdrawn compounding nominations with safety concerns. Approval of another melanocortin product is not approval of Melanotan II.
Selected abstracts and regulator warnings, not a full clinical review. Serious event reports need individual causality appraisal; no incidence estimate is assigned. Internet vial or nasal-spray identity, purity, PK and stability were not verified.
Melanocortin analogue with pigmentation and erectile effects in small early studies.
Its melanocortin activity can affect pigmentation and sexual responses. These pharmacological effects are not proof of a safe tanning method, UV protection or a validated sexual-health treatment.
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Very small escalating-dose pilot; no population incidence estimate.
Source · Abstract, adverse effects
Serious case reports, not demonstrated causality or event frequency.
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Source 1 · pubmed.ncbi.nlm.nih.gov
Melanotan II is a synthetic cyclic seven-amino-acid analogue of alpha-melanocyte-stimulating hormone. Small historical studies examined pigmentation and erections. It is a different compound from Melanotan I/afamelanotide and should not inherit that medicine’s product evidence.
Identity of studied MT-II; no equivalence to MT-I/afamelanotide.
Two of three volunteers in an early phase-I study showed increased pigmentation; the study was too small to establish long-term safety.
Three male volunteers; no long-term safety conclusion.
A crossover study in ten men with psychogenic erectile dysfunction observed erections in eight after Melanotan II; this does not establish a routine treatment regimen.
Ten men with psychogenic erectile dysfunction; not a general libido claim.
Early studies reported nausea, yawning/stretching, erections and, at higher pilot doses, somnolence or fatigue.
Very small escalating-dose pilot; no population incidence estimate.
FDA cites serious case reports including melanoma, prolonged erection (priapism), sympathomimetic toxicity and posterior reversible encephalopathy syndrome. Case reports do not establish incidence or prove causality.
Serious case reports, not demonstrated causality or event frequency.
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. 1996.
PMID: 8637402
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. 1998.
PMID: 9679884
FDA. Compounding safety concerns: Melanotan II. Checked September 7, 2026.
TGA. Don’t risk using tanning products containing melanotan. January 24, 2025; checked September 7, 2026.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.